Investor Presentaiton
June Quarter and Outlook
Product sales guidance reiterated of $30-33 million for FY22 (up 39-53% on FY21)4 and
gross margin above 70%
Continued improvement seen in US medical procedure numbers
New Myriad Morcells TM product line extension launched at Society for Advanced Wound Care conference
10-14 May 2021
✓ Large retrospective Endoform TM real-world study in diabetic foot ulcers concluded and submitted, with
publication expected in September quarter
45
AROA's dead space management system targeting an unmet need with an estimated US$2.5 billion 5
market was previewed with investors and three further patents filed relating to key aspects of this
technology
Manufacturing construction progressing to plan to expand capacity from NZ$35 million to NZ$100 million
in annual sales
TELA Bio, (AROA US partner selling OviTexTM and OviTex PRSTM) maintains its total revenue guidance of
US$27.0 million to US$30.0 million (48% to 65% over prior year period). With launch inventory levels now
consumed, AROA expects ongoing shipments to TELA Bio to correspond with increasing hospital demand
Guidance subject to no resurgence of COVID-19 in the US, continued improvement in US medical procedure numbers & TELA Bio sales performance. It assumes an average $NZD-$USD exchange rate of US$0.72
AROA management estimates
AROA™View entire presentation